NIKKEI 225
39,341.54 -325.53 (-0.82%) HANG SENG
17,716.47 -373.46 (-2.06%) CRUDE OIL
81.86 +0.96 (+1.19%) GOLD FUTURES
2,336.70 +23.50 (+1.02%) DOW
39,164.06 +36.26 (+0.09%) Bitcoin GBP
48,620.50 +520.76 (+1.08%)
AGIO Dec 2024 35.000 call
| Previous close | 11.75 |
| Open | 11.75 |
| Bid | 9.20 |
| Ask | 12.90 |
| Strike | 35.00 |
| Expiry date | 2024-12-20 |
| Day's range | 11.75 - 11.75 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
ZacksAgios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Simply Wall St.Swelling losses haven't held back gains for Agios Pharmaceuticals (NASDAQ:AGIO) shareholders since they're up 71% over 1 year
Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than...
GlobeNewswireAgios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements in Fatigue and Exercise Capacity in Patients Treated with Mitapivat Compared to Placebo – – Agios to Webcast Virtual Investor Event on June 16, 2024 at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time – CAMBRIDGE, Mass., June 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasd
